TY - JOUR
T1 - Selanylimidazopyridine abolishes inflammation- and stress-induced depressive-like behaviors by modulating the oxido-nitrosative system
AU - Domingues, Micaela
AU - Casaril, Angela Maria
AU - Smaniotto, Thiago Ângelo
AU - Birmann, Paloma Taborda
AU - Lourenço, Darling de Andrade
AU - Bampi, Suely Ribeiro
AU - Vieira, Beatriz
AU - Lenardão, Eder João
AU - Savegnago, Lucielli
N1 - Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2022/1/5
Y1 - 2022/1/5
N2 - The 3-[(4-methoxyphenyl)selanyl]-2-phenylimidazo[1,2-a] pyridine (MPI), a novel organic selenium compound, has been receiving increased attention due to its antioxidant effects and its ability to protect against depression-like behaviours. However, it remains elusive whether MPI is able to reverse depressive-like symptoms and biochemical alterations in mice. In the present work, we explored the ability of MPI (10 mg/kg, i.g.) to reverse inflammation- and stress-induced depression-like behaviours in mice injected with tumour necrosis factor (TNF-α) or submitted to acute restraint stress. Depression-like behaviours were evaluated by the tail suspension and splash test and the open field test was used to evaluate the locomotor activity of mice. The prefrontal cortex and hippocampus of mice were used for the evaluation of parameters of oxidonitrosative stress. Here, we showed that a single administration of MPI abolished the depressive-like behaviours induced by TNF-α and acute restraint stress. The oxidative and nitrosative stress presented in mice with depression-like behaviours were also decreased by MPI in the prefrontal cortex and hippocampus. Our findings suggest that MPI presents antidepressant-like activity which is associated with the biochemical regulation of oxidative stress in prefrontal cortex and hippocampus of mice, arising as a promising strategy for the management of depressive symptoms.
AB - The 3-[(4-methoxyphenyl)selanyl]-2-phenylimidazo[1,2-a] pyridine (MPI), a novel organic selenium compound, has been receiving increased attention due to its antioxidant effects and its ability to protect against depression-like behaviours. However, it remains elusive whether MPI is able to reverse depressive-like symptoms and biochemical alterations in mice. In the present work, we explored the ability of MPI (10 mg/kg, i.g.) to reverse inflammation- and stress-induced depression-like behaviours in mice injected with tumour necrosis factor (TNF-α) or submitted to acute restraint stress. Depression-like behaviours were evaluated by the tail suspension and splash test and the open field test was used to evaluate the locomotor activity of mice. The prefrontal cortex and hippocampus of mice were used for the evaluation of parameters of oxidonitrosative stress. Here, we showed that a single administration of MPI abolished the depressive-like behaviours induced by TNF-α and acute restraint stress. The oxidative and nitrosative stress presented in mice with depression-like behaviours were also decreased by MPI in the prefrontal cortex and hippocampus. Our findings suggest that MPI presents antidepressant-like activity which is associated with the biochemical regulation of oxidative stress in prefrontal cortex and hippocampus of mice, arising as a promising strategy for the management of depressive symptoms.
KW - Behaviour
KW - Depression
KW - Inflammation
KW - Selenium
KW - Stress
UR - http://www.scopus.com/inward/record.url?scp=85120824303&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120824303&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2021.174570
DO - 10.1016/j.ejphar.2021.174570
M3 - Article
C2 - 34653379
AN - SCOPUS:85120824303
SN - 0014-2999
VL - 914
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
M1 - 174570
ER -